EPISODE · May 5, 2014 · 13 MIN
Capecitabine Versus Continuous Infusion 5-FU for Rectal Cancer Neoadjuvant Chemoradiation: Equivalent Effectiveness Raises Real-World Questions About Efficacy, Adherence and Economic Implications
from Journal of Clinical Oncology (JCO) Podcast
This trial supports the use of neoadjuvant capecitabine monotherapy as a potentially more convenient radiosensitizer that does not sacrifice surgical and pathologic outcomes in rectal cancer. However, further study is needed.
Embed this episode
NOW PLAYING
Capecitabine Versus Continuous Infusion 5-FU for Rectal Cancer Neoadjuvant Chemoradiation: Equivalent Effectiveness Raises Real-World Questions About Efficacy, Adherence and Economic Implications
0:00
13:12
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 13 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on May 5, 2014.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!